medigraphic.com
ISSN 0001-0944 (Print)
Órgano Oficial de la Asociación Dental Mexicana

2021, Number 5

<< Back Next >>

Rev ADM 2021; 78 (5)

Mexico's vaccination process.

Orellana CJE, Guerrero SRN

Language: Spanish
References: 13
Page: 270-274
PDF size: 164.51 Kb.


ABSTRACT

Vaccination is an important process for all countries in the world as a preventive measure for the SARS-CoV-2 virus disease, the process of acquisition, distribution, priority of population groups to be vaccinated and the way to access them depends on each country. Mexico in gross rate is the third country in the world with the highest number of deaths and the importance of having vaccine and drugs for treatment is vital to reduce morbidity and mortality worldwide. The purpose of this essay is to present the process of distribution and development of vaccination in Mexico.


REFERENCES

  1. De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol. 2004; 2 (9): 704-720.

  2. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14 (1): 58-60.

  3. Mishra SK, Tripathi T. One year update on the COVID-19 pandemic: Where are we now? Acta Trop. 2021; 214: 105778.

  4. Lurie N, Sharfstein JM, Goodman JL. The development of COVID-19 vaccines: safeguards needed. JAMA. 2020; 324 (5): 439-440. doi: 10.1001/jama.2020.12461.

  5. Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 2020; 87 (4): 281-286.

  6. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al. A Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020; 382 (19): 1787-1799.

  7. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. Med Rxiv. 2020; 2020.2003.2017.20037432.

  8. Gobierno de México. Política Nacional de Vacunación contra el virus SARS-CoV-2, para la prevención de la COVID-19 en México. Documento Rector. Disponible en: https://coronavirus.gob.mx/wp-content/uploads/2021/01/PolVx_COVID_-11Ene2021.pdf

  9. Comisión Federal Para la Protección Contra Riesgos Sanitarios (COFEPRIS). Registro sanitario para uso de emergencia de producto con denominación distintiva Pfizer-BioNTech COVID-19 VACCINE. 11 de diciembre de 2020.

  10. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397 (10275): 671-681. doi: 10.1016/S0140-6736(21)00234-8.

  11. Dirección General de Epidemiología. Manual de procedimientos estandarizados para la vigilancia epidemiológica de eventos supuestamente atribuibles a la vacunación o inmunización (ESAVI). Disponible en: https://epidemiologia.salud.gob.mx/gobmx/salud/documentos/manuales/42_Manual_ESAVI.pdf

  12. Valadez B. Birmex pedirá registro de uso de emergencia para vacuna anticovid Sputnik V: Ssa. MILENIO. 01 de enero de 2021. Disponible en: https://www.milenio.com/politica/birmex-pedira-registro-emergencia-vacuna-sputnik

  13. Moreno M. Hugo López-Gatell explica sobre vacuna rusa Sputnik V. Imagen Radio. 02 de febrero de 2021. Disponible en: https://www.imagenradio.com.mx/hugo-lopez-gatell-explica-sobre-vacuna-rusa-sputnik-v




2020     |     www.medigraphic.com